LT-010391 for Advanced Solid Tumors With KRAS G12D Mutation
Part of Cancer, Digestive system, Lungs & breathing clinical trials.
This early-stage trial tests a new drug called LT-010391 designed to target a specific genetic mutation (KRAS G12D) found in some solid tumors. It's for patients whose cancer has progressed despite standard treatments or who cannot tolerate them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tumor must have a KRAS G12D genetic mutation confirmed by biopsy or tissue sample
- Your cancer must be advanced and either failed standard treatment, you couldn't tolerate standard treatment, or no standard treatment exists for your type
- You must be in good enough health to handle treatment (ECOG performance status 0–1, meaning you can do light activities or are mostly confined to bed/chair but not bedridden)
- Your liver, kidney, and blood cell counts must be adequate to tolerate the study drug
- You cannot have had 2 or more separate cancer diagnoses in the past 5 years (except certain skin cancers or cervical carcinoma in situ)
- Your cancer cannot involve the brain, spinal cord, or certain brain coverings (leptomeninges)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new drug called INV-8989 designed to target a specific genetic mutation (KRAS G12D) found in some advanced solid cancers. The study will evaluate whether the drug is safe and if it can help shrink tumors in patients who haven't responded to standard treatments.
This trial tests whether RMC-6236 can treat advanced solid tumors that have specific RAS-related gene changes (especially certain KRAS G12 mutations). You may be able to join if your tumor’s DNA test shows the right mutation and your overall health is good enough for study visits.
This trial tests a new drug called RMC-5127 for people with advanced solid tumors that have a specific KRAS G12V mutation. The study aims to see if this targeted therapy can help when other treatments have stopped working or caused side effects.
This study tests two oral medicines (elironrasib and daraxonrasib) given alone or together to see if they can shrink tumors or slow down cancer growth in people with advanced solid tumors that have a KRAS G12C mutation. It is for people who have already tried other treatments.
This trial tests a new drug (HS-10370) combined with other cancer treatments for people with advanced lung cancer that has a specific mutation called KRAS G12C. It is for those who have not yet received systemic therapy for their advanced disease.
This trial tests a new drug, HRS-6093, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and effective for those who have not responded to or cannot tolerate other treatments.
Hear when a new Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.